Akero Therapeutics Inc’s filing revealed that its Chief Development Officer Yale Catriona unloaded Company’s shares for reported $3.01 million on Jan 27 ’25. In the deal valued at $56.25 per share,53,590 shares were sold. As a result of this transaction, Yale Catriona now holds 95,648 shares worth roughly $5.15 million.
Then, Yale Catriona sold 49,074 shares, generating $2,734,212 in total proceeds. Upon selling the shares at $55.72, the Chief Development Officer now owns 95,648 shares.
Before that, Rolph Timothy sold 31,250 shares. Akero Therapeutics Inc shares valued at $1,742,958 were divested by the Chief Scientific Officer at a price of $55.77 per share. As a result of the transaction, Rolph Timothy now holds 170,237 shares, worth roughly $9.17 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -0.43% to $53.85. Over the last five days, the stock has gained 4.14%. Akero Therapeutics Inc shares have risen nearly 93.57% since the year began. Nevertheless, the stocks have risen 149.19% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $15.32 was recorded on 01/14/25. SMA at 50 days reached $31.49, while 200 days put it at $26.91.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 52.76, which if violated will result in even more drops to 51.66. On the upside, there is a resistance level at 54.82. A further resistance level may holdings at 55.78. The Relative Strength Index (RSI) on the 14-day chart is 82.26, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 17.52, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 12.28%. Stochastics %K at 89.29% indicates the stock is a selling.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-01-15, growing by 51522.0 shares to a total of 3.35 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 3.3 million shares. There was a rise of 1.54%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
